Skip to content
  • Home
  • Contact Us
  • About Us
  • Sitemap
  • Home
  • Contact Us
  • About Us
  • Sitemap
  • General
  • Business
  • Education
  • Government
  • Medical
  • Entertainment
  • Sports
  • French
  • Press Releases
    • PR-French
  • General
  • Business
  • Education
  • Government
  • Medical
  • Entertainment
  • Sports
  • French
  • Press Releases
    • PR-French
Search
Category: Press Releases

EBC Financial Group and the University of Oxford’s Department of Economics Announce WERD Episode on Macroeconomics and Climate

October 23, 2024

Balancing Economic Growth and Climate Resilience: A Global Discussion The upcoming WERD event, sponsored by EBC Financial Group, will feature a keynote lecture by Professor

Read More

EBC Financial Group and the University of Oxford’s Department of Economics Announce WERD Episode on Macroeconomics and Climate

October 23, 2024

Balancing Economic Growth and Climate Resilience: A Global Discussion The upcoming WERD event, sponsored by EBC Financial Group, will feature a keynote lecture by Professor

Read More

La plateforme Quantexa reconnue leader de sa catégorie dans le RiskTech Quadrant® pour ses solutions de connaissance du client

October 22, 2024

La plateforme Quantexa a obtenu une place de choix dans le rapport RiskTech100® 2025, soulignant ainsi sa force et son innovation sur le marché en

Read More

La plateforme Quantexa reconnue leader de sa catégorie dans le RiskTech Quadrant® pour ses solutions de connaissance du client

October 22, 2024

La plateforme Quantexa a obtenu une place de choix dans le rapport RiskTech100® 2025, soulignant ainsi sa force et son innovation sur le marché en

Read More

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

October 22, 2024

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds

Read More

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

October 22, 2024

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds

Read More
Page1 … Page367 Page368 Page369 Page370 Page371 … Page450
RECENT POSTS

WHO Warns Of A Record-breaking Ebola Outbreak In Congo

August 13, 2026

Conflict-Displaced Women in Eastern DRC Face Increasing Sexual Violence Risk

August 13, 2026

Ebola Outbreak in Eastern DR Congo Claims Over 300 Children; New Vaccine Trials Recommended

August 7, 2026

DR Congo Ebola Outbreak Surpasses 4,000 Cases Amidst Expanding Health Response

August 7, 2026

Ebola Cases Surpass 4,000 in Democratic Republic of Congo

August 7, 2026

Antwerp Confronts Colonial Past with Monument to Human Zoo Victims

August 7, 2026

Ebola Death Toll Tops 1,800 in DRC

August 7, 2026

DRCs Largest Ebola Outbreak on Record: Active Conflict and Armed Groups Hamper the Response

August 7, 2026
Copyright © 2026 Le Congo Tribune. All Rights Reserved.